GlassScriptPhysician profile
Dustin Warbritton
NPI 1093712275
$9,775.15
in general payments reported to CMS, 2019-2025
55 companies · $38.54 in 2025
The $38.54 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,867 · 2020: $1,494 · 2021: $2,221 · 2022: $1,960 · 2023: $2,179 · 2024: $16.18 · 2025: $38.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157 · Education: $75.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,157.35 |
| Education | $75.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,322.79 | 2020-2023 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $1,062.63 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $809.54 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $730.49 | 2019-2023 | Farxiga, Breztri |
| Amgen INC. | $577.26 | 2019-2023 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $496.45 | 2019-2023 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $383.56 | 2019-2023 | Veozah |
| Allergan, INC. | $365.43 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.28 | 2019-2023 | Jardiance, Spiriva Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $270.37 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $249.90 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $248.63 | 2019-2023 | Xarelto |
| Abbott Laboratories | $234.49 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $227.77 | 2019-2023 | Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $167.42 | 2020-2023 | Verquvo, Belsomra, Steglatro |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Warbritton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.